Pacira BioSciences (NASDAQ:PCRX) Price Target Lowered to $30.00 at Needham & Company LLC

Pacira BioSciences (NASDAQ:PCRX) had its target price decreased by Needham & Company LLC from $32.00 to $30.00 in a research report report published on Friday morning,Benzinga reports. Needham & Company LLC currently has a buy rating on the stock.

Several other research analysts have also recently weighed in on the company. Barclays upped their price objective on Pacira BioSciences from $17.00 to $24.00 and gave the stock an “overweight” rating in a research report on Friday, February 28th. Royal Bank of Canada reissued a “sector perform” rating and issued a $18.00 price objective on shares of Pacira BioSciences in a research report on Tuesday, January 14th. HC Wainwright raised their target price on shares of Pacira BioSciences from $48.00 to $65.00 and gave the company a “buy” rating in a research report on Tuesday, April 8th. Finally, Truist Financial upgraded shares of Pacira BioSciences from a “sell” rating to a “hold” rating and increased their price objective for the stock from $8.00 to $25.00 in a research note on Thursday, January 30th. One research analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $26.44.

Pacira BioSciences Trading Up 0.8 %

Shares of NASDAQ:PCRX opened at $25.12 on Friday. The firm has a market cap of $1.16 billion, a price-to-earnings ratio of -12.37 and a beta of 0.56. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51. Pacira BioSciences has a 12 month low of $11.16 and a 12 month high of $31.67. The company’s fifty day simple moving average is $24.73 and its 200 day simple moving average is $22.10.

Institutional Investors Weigh In On Pacira BioSciences

Institutional investors have recently made changes to their positions in the company. Sterling Capital Management LLC boosted its stake in Pacira BioSciences by 779.4% in the 4th quarter. Sterling Capital Management LLC now owns 1,363 shares of the company’s stock valued at $26,000 after purchasing an additional 1,208 shares during the period. Ancora Advisors LLC acquired a new stake in shares of Pacira BioSciences during the fourth quarter worth $26,000. Caitlin John LLC boosted its position in shares of Pacira BioSciences by 1,850.0% in the fourth quarter. Caitlin John LLC now owns 1,872 shares of the company’s stock valued at $35,000 after acquiring an additional 1,776 shares during the period. US Bancorp DE grew its stake in shares of Pacira BioSciences by 31.0% in the first quarter. US Bancorp DE now owns 2,270 shares of the company’s stock valued at $56,000 after acquiring an additional 537 shares in the last quarter. Finally, Wealthquest Corp bought a new position in Pacira BioSciences during the first quarter worth about $59,000. Institutional investors own 99.73% of the company’s stock.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.